American Century Companies Inc. grew its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 7.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 262,991 shares of the company’s stock after purchasing an additional 17,363 shares during the period. American Century Companies Inc.’s holdings in Takeda Pharmaceutical were worth $3,403,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Bleakley Financial Group LLC raised its stake in Takeda Pharmaceutical by 19.1% during the 1st quarter. Bleakley Financial Group LLC now owns 288,535 shares of the company’s stock worth $4,008,000 after buying an additional 46,182 shares during the period. Envestnet Portfolio Solutions Inc. raised its position in shares of Takeda Pharmaceutical by 7.4% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 25,763 shares of the company’s stock worth $358,000 after purchasing an additional 1,778 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in shares of Takeda Pharmaceutical by 0.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 130,904 shares of the company’s stock worth $1,818,000 after purchasing an additional 857 shares during the period. OLD Mission Capital LLC lifted its holdings in shares of Takeda Pharmaceutical by 1,440.9% in the 4th quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock worth $14,863,000 after purchasing an additional 973,935 shares in the last quarter. Finally, Van ECK Associates Corp grew its position in Takeda Pharmaceutical by 21.1% in the 2nd quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock valued at $26,408,000 after purchasing an additional 356,069 shares during the period. Institutional investors own 9.17% of the company’s stock.
Takeda Pharmaceutical Stock Performance
TAK opened at $14.65 on Friday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $16.06. The company has a market cap of $46.61 billion, a price-to-earnings ratio of 26.64, a PEG ratio of 0.27 and a beta of 0.54. The company’s fifty day moving average price is $14.40 and its two-hundred day moving average price is $13.76. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Articles
- Five stocks we like better than Takeda Pharmaceutical
- What Makes a Stock a Good Dividend Stock?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Stock Sentiment Analysis: How it Works
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- CD Calculator: Certificate of Deposit Calculator
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.